Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Adaptations and modifications to a co-designed intervention and its clinical implementation: a qualitative study in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Understanding what matters most to patients in acute care in seven countries, using the flash mob study design.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sarah Alulis
  • Kasper Vadstrup
  • Jens Olsen
  • Tine Rikke Jørgensen
  • Niels Qvist
  • Pia Munkholm
  • Andras Borsi
Vis graf over relationer

BACKGROUND: Patients diagnosed with inflammatory bowel disease may be treated with biologics, depending on several medical and non-medical factors. This study investigated healthcare costs and production values of patients treated with biologics.

METHODS: This national register study included patients diagnosed with Crohn's disease (CD) and ulcerative colitis (UC) between 2003 and 2015, identified in the Danish National Patient Register (DNPR). Average annual healthcare costs and production values were compared for patients receiving biologic treatment or not, and for patients initiating biologic treatment within a year after diagnosis or at a later stage. Cost estimates and production values were based on charges, fees and average gross wages.

RESULTS: Twenty-six point one percent CD patients and ten point seven percent of UC patients were treated with biologics at some point in the study period. Of these, 46.4 and 45.5 % of patients initiated biologic treatment within the first year after diagnosis. CD and UC patients treated with biologics had higher average annual healthcare costs after diagnosis compared to patients not treated with biologics. CD patients receiving biologics early had lower production values both ten years before and eight years after treatment initiation, compared to patients receiving treatment later. UC patients receiving biologics early had lower average annual production values the first year after treatment initiation compared to UC patients receiving treatment later.

CONCLUSIONS: CD and UC patients receiving biologic treatment had higher average annual healthcare costs and lower average annual production values, compared to patients not receiving biologic treatment. The main healthcare costs drivers were outpatient visit costs and admission costs.

OriginalsprogEngelsk
Artikelnummer836
TidsskriftBMC Health Services Research
Vol/bind21
Udgave nummer1
Sider (fra-til)836
ISSN1472-6963
DOI
StatusUdgivet - 18 aug. 2021

ID: 67148770